"Several ongoing trials hope to further elucidate the role of lurbinectedin in highgrade neuroendocrine neoplasms [...]" BUFFALO, NY- October 6, 2023 – A new editorial paper was published in Oncoscience ( Volume 10 ) on June 14, 2023, entitled, " Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer ." In their new editorial, researchers Deepak Bhamidipati and Vivek Subbiah from the Sarah Cannon Research Institute discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs).

https://www.miragenews.com/lurbinectedin-shows-promise-for-neuroendocrine-1099075/

#miragenews